Isomorphic Labs, the drug-discovery company spun out of Google’s DeepMind in 2021, has closed a $5 billion Series C. TechCrunch reported the round on November 17. The money is meant to carry its drug candidates toward clinical trials.

Greenoaks and Sequoia Capital co-led. Andreessen Horowitz joined as a new investor, and every existing backer returned: GV, CapitalG, Thrive Capital, MGX, Temasek, and the U.K. Sovereign AI Fund. The round follows a $2.1 billion Series B in May.

The company builds a drug-design engine from simulation models, building on DeepMind’s AlphaFold protein-structure work. It reports positive preclinical results in oncology and immunology, and it has deals with Eli Lilly, Novartis, and Johnson & Johnson. Those results are the company’s own claim; no data accompanied the announcement.

Isomorphic did not disclose a valuation. Bloomberg had reported in November that the lab sought $50 billion. For now, the proof point that matters is a first candidate dosed in a human trial.

TechCrunch, November 17, 2026.